Prestige Consumer Healthcare Debt to Equity Ratio 2010-2024 | PBH
Current and historical debt to equity ratio values for Prestige Consumer Healthcare (PBH) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Prestige Consumer Healthcare debt/equity for the three months ending September 30, 2024 was 0.61.
| Prestige Consumer Healthcare Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-09-30 | $1.59B | $1.73B | 0.92 |
| 2024-06-30 | $1.63B | $1.68B | 0.97 |
| 2024-03-31 | $1.66B | $1.66B | 1.01 |
| 2023-12-31 | $1.74B | $1.60B | 1.09 |
| 2023-09-30 | $1.80B | $1.54B | 1.17 |
| 2023-06-30 | $1.87B | $1.48B | 1.26 |
| 2023-03-31 | $1.91B | $1.45B | 1.32 |
| 2022-12-31 | $2.06B | $1.69B | 1.22 |
| 2022-09-30 | $2.06B | $1.62B | 1.27 |
| 2022-06-30 | $2.10B | $1.59B | 1.32 |
| 2022-03-31 | $2.09B | $1.58B | 1.33 |
| 2021-12-31 | $2.14B | $1.52B | 1.41 |
| 2021-09-30 | $2.21B | $1.46B | 1.52 |
| 2021-06-30 | $2.14B | $1.42B | 1.51 |
| 2021-03-31 | $2.07B | $1.36B | 1.53 |
| 2020-12-31 | $2.15B | $1.32B | 1.62 |
| 2020-09-30 | $2.16B | $1.28B | 1.69 |
| 2020-06-30 | $2.22B | $1.23B | 1.81 |
| 2020-03-31 | $2.34B | $1.17B | 2.00 |
| 2019-12-31 | $2.31B | $1.16B | 2.00 |
| 2019-09-30 | $2.35B | $1.11B | 2.11 |
| 2019-06-30 | $2.36B | $1.10B | 2.14 |
| 2019-03-31 | $2.35B | $1.10B | 2.14 |
| 2018-12-31 | $2.44B | $1.23B | 1.98 |
| 2018-09-30 | $2.50B | $1.19B | 2.10 |
| 2018-06-30 | $2.61B | $1.16B | 2.24 |
| 2018-03-31 | $2.58B | $1.18B | 2.19 |
| 2017-12-31 | $2.68B | $1.22B | 2.20 |
| 2017-09-30 | $3.01B | $0.90B | 3.36 |
| 2017-06-30 | $3.04B | $0.86B | 3.54 |
| 2017-03-31 | $3.09B | $0.82B | 3.76 |
| 2016-12-31 | $2.01B | $0.80B | 2.51 |
| 2016-09-30 | $2.06B | $0.78B | 2.66 |
| 2016-06-30 | $2.14B | $0.74B | 2.90 |
| 2016-03-31 | $2.20B | $0.74B | 2.96 |
| 2015-12-31 | $1.92B | $0.72B | 2.66 |
| 2015-09-30 | $1.94B | $0.69B | 2.83 |
| 2015-06-30 | $1.97B | $0.66B | 2.98 |
| 2015-03-31 | $2.01B | $0.63B | 3.21 |
| 2014-12-31 | $2.07B | $0.61B | 3.40 |
| 2014-09-30 | $2.13B | $0.59B | 3.59 |
| 2014-06-30 | $1.27B | $0.59B | 2.17 |
| 2014-03-31 | $1.23B | $0.56B | 2.19 |
| 2013-12-31 | $1.32B | $0.54B | 2.43 |
| 2013-09-30 | $1.27B | $0.54B | 2.34 |
| 2013-06-30 | $1.24B | $0.50B | 2.47 |
| 2013-03-31 | $1.26B | $0.48B | 2.64 |
| 2012-12-31 | $1.27B | $0.46B | 2.79 |
| 2012-09-30 | $1.35B | $0.44B | 3.08 |
| 2012-06-30 | $1.33B | $0.42B | 3.19 |
| 2012-03-31 | $1.36B | $0.40B | 3.37 |
| 2011-12-31 | $0.64B | $0.40B | 1.60 |
| 2011-09-30 | $0.66B | $0.39B | 1.70 |
| 2011-06-30 | $0.67B | $0.38B | 1.78 |
| 2011-03-31 | $0.70B | $0.36B | 1.92 |
| 2010-12-31 | $0.70B | $0.36B | 1.97 |
| 2010-09-30 | $0.44B | $0.35B | 1.25 |
| 2010-06-30 | $0.44B | $0.34B | 1.28 |
| 2010-03-31 | $0.46B | $0.33B | 1.41 |
| 2009-12-31 | $0.46B | $0.33B | 1.42 |
| 2009-09-30 | $0.49B | $0.31B | 1.55 |
| 2009-06-30 | $0.49B | $0.30B | 1.63 |
| 2009-03-31 | $0.51B | $0.29B | 1.72 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $4.074B | $1.125B |
| Prestige Consumer Healthcare Inc. is a consumer healthcare products company. Its diverse portfolio of brands include Monistat(R) and Summer's Eve(R) women's health products, BC(R) and Goody's(R) pain relievers, Clear Eyes(R) and TheraTears(R) eye care products, DenTek(R) specialty oral care products, Dramamine(R) motion sickness treatments, Fleet(R) enemas and glycerin suppositories, Chloraseptic(R) and Luden's(R) sore throat treatments and drops, Compound W(R) wart treatments, Little Remedies(R) pediatric over-the-counter products, Boudreaux's Butt Paste(R) diaper rash ointments, Nix(R) lice treatment, Debrox(R) earwax remover, Gaviscon(R) antacid in Canada, and Hydralyte(R) rehydration products and the Fess(R) line of nasal and sinus care products in Australia. Prestige Consumer Healthcare Inc., formerly known as Prestige Brands Holdings Inc., is based in Tarrytown, New York. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $203.157B | 25.91 |
| Stryker (SYK) | United States | $148.171B | 33.39 |
| Boston Scientific (BSX) | United States | $133.131B | 38.28 |
| EssilorLuxottica (ESLOY) | France | $113.461B | 0.00 |
| Medtronic (MDT) | Ireland | $109.010B | 16.19 |
| Haleon (HLN) | United Kingdom | $42.913B | 27.88 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.122B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $37.701B | 19.56 |
| ResMed (RMD) | United States | $34.955B | 28.72 |
| Terumo (TRUMY) | Japan | $29.203B | 41.24 |
| Koninklijke Philips (PHG) | Netherlands | $24.410B | 18.68 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.087B | 14.06 |
| Insulet (PODD) | United States | $18.377B | 73.18 |
| Baxter (BAX) | United States | $16.604B | 10.80 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.153B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.468B | 37.96 |
| Bio-Rad Laboratories (BIO) | United States | $8.977B | 30.51 |
| Demant (WILYY) | Denmark | $8.342B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.523B | 12.83 |
| TG Therapeutics (TGTX) | United States | $4.720B | 0.00 |
| Haemonetics (HAE) | United States | $4.260B | 20.79 |
| ICU Medical (ICUI) | United States | $4.155B | 39.56 |
| Perrigo (PRGO) | Ireland | $3.716B | 10.94 |
| Envista Holdings (NVST) | United States | $3.487B | 25.97 |
| Neogen (NEOG) | United States | $3.270B | 37.72 |
| Agios Pharmaceuticals (AGIO) | United States | $3.103B | 0.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.789B | 17.89 |
| QuidelOrtho (QDEL) | United States | $2.595B | 16.70 |
| Warby Parker (WRBY) | United States | $2.344B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $2.332B | 56.69 |
| Green Thumb Industries (GTBIF) | United States | $1.964B | 34.37 |
| AtriCure (ATRC) | United States | $1.772B | 0.00 |
| InMode (INMD) | Israel | $1.487B | 8.94 |
| Curaleaf Holdings (CURLF) | Canada | $1.348B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.311B | 9.37 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.168B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.041B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.962B | 16.96 |
| Owens & Minor (OMI) | United States | $0.957B | 7.48 |
| CeriBell (CBLL) | United States | $0.916B | 0.00 |
| National Vision Holdings (EYE) | United States | $0.888B | 29.68 |
| Capricor Therapeutics (CAPR) | United States | $0.839B | 0.00 |
| Evolus (EOLS) | United States | $0.785B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.608B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.596B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.596B | 26.47 |
| Surmodics (SRDX) | United States | $0.559B | 0.00 |
| Quanterix (QTRX) | United States | $0.424B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.404B | 0.00 |
| Valneva SE (VALN) | France | $0.370B | 0.00 |
| ZimVie (ZIMV) | United States | $0.363B | 30.63 |
| Omeros (OMER) | United States | $0.349B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.335B | 31.89 |
| Biote (BTMD) | United States | $0.330B | 7.25 |
| Sanara MedTech (SMTI) | United States | $0.323B | 0.00 |
| Cerus (CERS) | United States | $0.312B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.288B | 19.30 |
| Zynex (ZYXI) | United States | $0.249B | 52.13 |
| TerrAscend (TSNDF) | Canada | $0.243B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.229B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.219B | 15.15 |
| MacroGenics (MGNX) | United States | $0.218B | 0.00 |
| High Tide (HITI) | Canada | $0.215B | 89.00 |
| Sanuwave Health (SNWV) | United States | $0.195B | 2.74 |
| Jin Medical (ZJYL) | China | $0.188B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.162B | 0.00 |
| Brainsway (BWAY) | Israel | $0.161B | 96.70 |
| Organigram Holdings (OGI) | Canada | $0.158B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.143B | 17.98 |
| TriSalus Life Sciences (TLSI) | United States | $0.126B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.106B | 0.00 |
| Fonar (FONR) | United States | $0.093B | 10.54 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 23.00 |
| Veru (VERU) | United States | $0.092B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.082B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.080B | 41.50 |
| Modular Medical (MODD) | United States | $0.073B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.070B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.066B | 0.00 |
| InterCure (INCR) | Israel | $0.063B | 0.00 |
| Exagen (XGN) | United States | $0.062B | 0.00 |
| MariMed (MRMD) | United States | $0.059B | 0.00 |
| Safety Shot (SHOT) | United States | $0.056B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.052B | 0.00 |
| Apyx Medical (APYX) | United States | $0.048B | 0.00 |
| ImmuCell (ICCC) | United States | $0.032B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.026B | 0.00 |
| Flora Growth (FLGC) | United States | $0.018B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.011B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 13.17 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |